117 related articles for article (PubMed ID: 32588421)
41. Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study.
Gundlund A; Olesen JB; Staerk L; Lee C; Piccini JP; Peterson ED; Køber L; Torp-Pedersen C; Gislason GH; Fosbøl EL
J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27866162
[TBL] [Abstract][Full Text] [Related]
42. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
43. Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation.
Koga M; Yoshimura S; Hasegawa Y; Shibuya S; Ito Y; Matsuoka H; Takamatsu K; Nishiyama K; Todo K; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Yagita Y; Kario K; Shiozawa M; Sato S; Yamagami H; Arihiro S; Toyoda K;
Stroke; 2016 Oct; 47(10):2582-8. PubMed ID: 27531346
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
45. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation.
Seiffge DJ; Paciaroni M; Wilson D; Koga M; Macha K; Cappellari M; Schaedelin S; Shakeshaft C; Takagi M; Tsivgoulis G; Bonetti B; Kallmünzer B; Arihiro S; Alberti A; Polymeris AA; Ambler G; Yoshimura S; Venti M; Bonati LH; Muir KW; Yamagami H; Thilemann S; Altavilla R; Peters N; Inoue M; Bobinger T; Agnelli G; Brown MM; Sato S; Acciarresi M; Jager HR; Bovi P; Schwab S; Lyrer P; Caso V; Toyoda K; Werring DJ; Engelter ST; De Marchis GM;
Ann Neurol; 2019 Jun; 85(6):823-834. PubMed ID: 30980560
[TBL] [Abstract][Full Text] [Related]
46. T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort.
Pastori D; Carnevale R; Stanzione R; Nocella C; Cotugno M; Marchitti S; Bianchi F; Forte M; Valenti V; Biondi-Zoccai G; Schiavon S; Vecchio D; Versaci F; Frati G; Violi F; Volpe M; Pignatelli P; Rubattu S; Sciarretta S
Int J Cardiol; 2021 Jan; 322():245-249. PubMed ID: 32861716
[TBL] [Abstract][Full Text] [Related]
47. [Incidence of complications of antithrombotic treatment in patients with atrial fibrillation].
Novaković Anucin S; Gnip S; Canak V; Radović P; Kovacev J; Mitić G
Med Pregl; 2013; 66(11-12):470-5. PubMed ID: 24575635
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
49. Effects of body mass index on risks for ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation patients: a single-center experience.
Wang HJ; Si QJ; Shan ZL; Guo YT; Lin K; Zhao XN; Wang YT
PLoS One; 2015; 10(4):e0123516. PubMed ID: 25848965
[TBL] [Abstract][Full Text] [Related]
50. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
Van Der Meersch H; De Bacquer D; De Vriese AS
Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
[TBL] [Abstract][Full Text] [Related]
51. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators.
JAMA; 1998 Apr 22-29; 279(16):1273-7. PubMed ID: 9565007
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
[No Abstract] [Full Text] [Related]
53. Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.
Pastori D; Pignatelli P; Farcomeni A; Cangemi R; Hiatt WR; Bartimoccia S; Nocella C; Vicario T; Bucci T; Carnevale R; Lip GY; Violi F
Am Heart J; 2015 Sep; 170(3):490-7.e1. PubMed ID: 26385032
[TBL] [Abstract][Full Text] [Related]
54. Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study.
Vedovati MC; Giustozzi M; Verdecchia P; Pierpaoli L; Conti S; Verso M; Di Filippo F; Marchesini E; Bogliari G; Agnelli G; Becattini C
Int J Cardiol; 2018 Oct; 269():152-157. PubMed ID: 30077526
[TBL] [Abstract][Full Text] [Related]
55. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
van Walraven C; Hart RG; Singer DE; Laupacis A; Connolly S; Petersen P; Koudstaal PJ; Chang Y; Hellemons B
JAMA; 2002 Nov; 288(19):2441-8. PubMed ID: 12435257
[TBL] [Abstract][Full Text] [Related]
56. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
Ukaigwe A; Shrestha P; Karmacharya P; Hussain SK; Samii S; Gonzalez MD; Wolbrette D; Naccarrelli GV
J Interv Card Electrophysiol; 2017 Mar; 48(2):223-233. PubMed ID: 27771820
[TBL] [Abstract][Full Text] [Related]
57. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.
Pastori D; Farcomeni A; Poli D; Antonucci E; Angelico F; Del Ben M; Cangemi R; Tanzilli G; Lip GY; Pignatelli P; Violi F
Intern Emerg Med; 2016 Mar; 11(2):199-204. PubMed ID: 26471883
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
Cavallari I; Verolino G; Romano S; Patti G
Thromb Haemost; 2020 Feb; 120(2):314-321. PubMed ID: 31785599
[TBL] [Abstract][Full Text] [Related]
59. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
Banerjee A; Clementy N; Haguenoer K; Fauchier L; Lip GY
Am J Med; 2014 Oct; 127(10):972-8. PubMed ID: 24929021
[TBL] [Abstract][Full Text] [Related]
60. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands.
Vermond RA; Geelhoed B; Verweij N; Tieleman RG; Van der Harst P; Hillege HL; Van Gilst WH; Van Gelder IC; Rienstra M
J Am Coll Cardiol; 2015 Sep; 66(9):1000-7. PubMed ID: 26314526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
